Colorcon launches new enteric coating with pH up to 5.0
Acryl-EZE formulations provide significant time savings and targeted drug delivery.
Colorcon has launched Acryl-EZE II, which extends the pH range covered by its enteric coatings.
Delayed-release oral solid dosage forms developed with enteric coating provide either protection of the gastric mucosa from irritating actives or protection of drugs unstable in gastric fluids.
Applications include tablets and multiparticulate dosages for a range of drug products, including proton pump inhibitors (PPIs), which are commonly used to treat acid reflux and ulcers of the stomach and the duodenum.
Acryl-EZE II extends Colorcon‘s line of aqueous enteric systems to provide specific applications for tablets and multiparticulate dosage forms with enhanced enteric protection up to a challenging level of pH 5.0 seen with patients taking PPIs, or when tested under fed conditions.
According to Kelly Boyer, General Manager Film Coatings this extension to the company's portfolio of products represents "an advance in delayed-release coating technology" to provide the pharmaceutical industry with added convenience for enteric coating.
"Acryl-EZE formulations provide significant time savings in both development and production while enabling targeted drug delivery across a wide pH range,” said Kelly.
The formulation of enteric coatings is challenging; it requires multiple ingredients and process steps. Dr Ali Rajabi-Siahboomi, Colorcon's Vice President and Chief Scientific Officer, explained that through Colorcon’s coating technology, this new Acryl-EZE II formulation provides "simplified preparation and use", with enhanced protection up to pH 5.0 through the addition of a special top-coat.
Coating performance has been validated through a human volunteer study in the most challenging fed state conditions, confirming bioavailability and in vivo performance.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance